Incyte, Courting New Role as Drug Developer, Names New CEO, President, and CSO | GenomeWeb

SAN FRANCISCO, Nov. 26 - Incyte Genomics said on Monday that co-founder Roy Whitfield has been replaced as CEO by Paul Friedman, formerly the president of DuPont Pharmaceuticals Research Laboratories, in a move that underscores Incyte's intent to move swiftly from a genomics database provider to a profitable drug developer.

 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: global genetic diversity map, and more.

The Nuffield Council on Bioethics identifies ethical questions to explore surrounding genome editing.

In a blog post, Brigham and Women's Hospital's Robert Green discusses "predispositional personal genome sequencing."

Stat News reports that there's muted opposition to the Kuwaiti DNA database law.